Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Something is cooking!!!

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Aug 22, 2023 4:55pm

54 Views

Post# 35600651

RE:RE:RE:RE:RE:RE:Something is cooking!!!

Adding at such a low price after a reverse split does wonders to the average cost .....still need the Sp to reverse course and head north of course

palinc2000 wrote:
Quadrupling would bring market cap to 100 million just based on positive ebitda.....
There has been a lot of technical damage ..... time can heal everyting but not overnight without some major positive news
You are not crazy and far from it but logic seems to be out of the equation at this moment
All I want now are steps that go up versus steps that go down and down

juniper88 wrote: Quadruple PPS would be CAD $5.32/share or $1.33/share pre-split. So, about where we were a couple of months ago.

Call me crazy but I would like at least CAD $7/share pre-split (basically $28/share)

palinc2000 wrote:

Worst case we get completely wiped out...if sales dont contribute enough to reach positive Ebitda ....They have forecasted that sales would reach a high enough level to generate enough cash,,,I am cautiously optimistic that the guidance will be met,..
If the positive EBITDA is met then we should at least triple or quadruple the SP and more
Signing deals with partners would have a positive impact of course but hard to quantify without more details

Lee430 wrote: Palinc, How do you see us shareholder fairing in your possible scenarios? What do you think the worst case or best case might be?

palinc2000 wrote: I may be interpreting this wrong but the newly released Coporate Presentation is like a Term Sheet to be presented to eventual acquirer(s/partners ) in whole or in part .....
They will reduce expenses to the minimum until resolution

palinc2000 wrote: Restructuring? Take over? Merger? Partnering?
I may be wrong but the only other explanation would be that there has been a gas leak in the Head Office and they are all sleeping LOL!!!